Thank You Letter

I received this today, it touched me deeply, and I received permission to share with site readers:



Hello, my name is Brendon. I am e-mailing you for many reasons after looking at your site. Before I explain myself, I'd like to introduce myself. I am 18 years of age, and am very interested in Non-Hodgkin’s Lymphoma. I found your site through Google search. I was searching for Lymphoma as a research topic for my High School health class, and your site was the first result.
The reason I admire your site is that it is not some doctor explaining what it is, it's a survivor.

Now the reason I am so interested in this disease is because my mother was diagnosed with Non-Hodgkin’s Lymphoma, and fought it for a good 4 years. She passed away from the disease on June 8th, 2003. That's how I know about it and am so interested about it. Basically I would like to know every last detail about what took my mother away from me.

So far, I have gone to 50+ sites about this disease, and so far, yours is the best. Unlike doctors who know about it, you lived through it, and you have much respect from me.

The information on your site has been much appreciated. I know a lot more stuff about this disease now, more then I even hoped for.
Basically, I am typing up this e-mail to say thank you for providing people this information, because some of us, like myself, want to know as much about it as possible.

So again, thank you. Take care, and have a wonderful day.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap